Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Share-based Compensation (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Share-based Compensation data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 132.19% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $4.9 million, up 52.02%, while the annual FY2024 figure was $1.8 million, 81.85% down from the prior year.
  • Share-based Compensation reached $1.6 million in Q3 2025 per SNTI's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.2 million in Q2 2022 and bottomed at -$776000.0 in Q2 2024.
  • Average Share-based Compensation over 5 years is $2.0 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 473.61% in 2022, then crashed 122.6% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $735000.0 in 2021, then surged by 473.61% to $4.2 million in 2022, then plummeted by 51.04% to $2.1 million in 2023, then crashed by 70.69% to $605000.0 in 2024, then soared by 156.36% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.6 million in Q3 2025, $1.5 million in Q2 2025, and $1.2 million in Q1 2025.